Posted On: 11/17/2014 2:06:18 AM
Post# of 250675
Accentia Biopharmaceuticals Inc. (ABPI) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Accentia Biopharmaceuticals Inc.
Fiscal year is October-September. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 15.92M 10.56M 5.36M 3.96M 4.05M
Cost of Goods Sold (COGS) incl. D&A 9.66M 7.84M 2.9M 2.49M 2.77M
COGS excluding D&A 7.88M 7.36M 2.31M 1.93M 2.52M
Depreciation & Amortization Expense 1.77M 482,163 592,265 561,766 249,840
Depreciation 709,902 248,666 273,870 102,976 147,285
Amortization of Intangibles 1.06M 233,497 318,395 458,790 102,555
Gross Income 6.27M 2.72M 2.45M 1.47M 1.28M
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 33.03M 9.53M 5.64M 22.61M 12.78M
Research & Development 8.92M 1.32M 1.3M 2.23M 5.24M
Other SG&A 24.11M 8.21M 4.34M 20.38M 7.55M
Other Operating Expense 20,000 20,000 20,000 30,000 40,000
Unusual Expense 7.21M (8.3M) 28.13M (13.41M) (7.03M)
EBIT after Unusual Expense (7.21M) 8.3M (28.13M) 13.41M 7.03M
Non Operating Income/Expense 739,881 (422,050) (210,307) 202,031 (13,496)
Non-Operating Interest Income - - - - 0
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 28.06M 8.44M 16.66M 8.09M 7.91M
Gross Interest Expense 28.06M 8.44M 16.66M 8.09M 7.91M
Interest Capitalized 0 0 0 0 0
Pretax Income (61.3M) (7.4M) (48.21M) (15.65M) (12.43M)
Income Tax 0 4,840 3,156 4,705 0
Income Tax - Current Domestic 0 - 3,156 4,705 -
Income Tax - Current Foreign 0 - - - -
Income Tax - Deferred Domestic 0 - - - -
Income Tax - Deferred Foreign 0 - - - -
Income Tax Credits 0 - 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) - - 0 0 0
Consolidated Net Income (61.3M) (7.4M) (48.21M) (15.65M) (12.43M)
Minority Interest Expense (513,136) (454,926) (411,711) (4.1M) (4.87M)
Net Income (60.79M) (6.95M) (47.8M) (11.55M) (7.56M)
Extraordinaries & Discontinued Operations 0 1.68M 0 0 3.24M
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 1.68M - - 3.24M
Net Income After Extraordinaries (60.79M) (5.26M) (47.8M) (11.55M) (4.32M)
Preferred Dividends 2.77M 2.8M 2.33M 0 0
Net Income Available to Common (63.56M) (9.75M) (50.13M) (11.55M) (7.56M)
EPS (Basic) (1.38) (0.14) (0.86) (0.17) (0.05)
Basic Shares Outstanding 45.9M 58.03M 58.05M 68.44M 80.74M
EPS (Diluted) (1.38) (0.14) (0.86) (0.17) (0.05)
Diluted Shares Outstanding 45.9M 58.03M 58.05M 68.44M 80.74M
EBITDA (25.01M) (6.35M) (2.62M) (20.61M) (11.29M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Accentia Biopharmaceuticals Inc.
Fiscal year is October-September. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 15.92M 10.56M 5.36M 3.96M 4.05M
Cost of Goods Sold (COGS) incl. D&A 9.66M 7.84M 2.9M 2.49M 2.77M
COGS excluding D&A 7.88M 7.36M 2.31M 1.93M 2.52M
Depreciation & Amortization Expense 1.77M 482,163 592,265 561,766 249,840
Depreciation 709,902 248,666 273,870 102,976 147,285
Amortization of Intangibles 1.06M 233,497 318,395 458,790 102,555
Gross Income 6.27M 2.72M 2.45M 1.47M 1.28M
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 33.03M 9.53M 5.64M 22.61M 12.78M
Research & Development 8.92M 1.32M 1.3M 2.23M 5.24M
Other SG&A 24.11M 8.21M 4.34M 20.38M 7.55M
Other Operating Expense 20,000 20,000 20,000 30,000 40,000
Unusual Expense 7.21M (8.3M) 28.13M (13.41M) (7.03M)
EBIT after Unusual Expense (7.21M) 8.3M (28.13M) 13.41M 7.03M
Non Operating Income/Expense 739,881 (422,050) (210,307) 202,031 (13,496)
Non-Operating Interest Income - - - - 0
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 28.06M 8.44M 16.66M 8.09M 7.91M
Gross Interest Expense 28.06M 8.44M 16.66M 8.09M 7.91M
Interest Capitalized 0 0 0 0 0
Pretax Income (61.3M) (7.4M) (48.21M) (15.65M) (12.43M)
Income Tax 0 4,840 3,156 4,705 0
Income Tax - Current Domestic 0 - 3,156 4,705 -
Income Tax - Current Foreign 0 - - - -
Income Tax - Deferred Domestic 0 - - - -
Income Tax - Deferred Foreign 0 - - - -
Income Tax Credits 0 - 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) - - 0 0 0
Consolidated Net Income (61.3M) (7.4M) (48.21M) (15.65M) (12.43M)
Minority Interest Expense (513,136) (454,926) (411,711) (4.1M) (4.87M)
Net Income (60.79M) (6.95M) (47.8M) (11.55M) (7.56M)
Extraordinaries & Discontinued Operations 0 1.68M 0 0 3.24M
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 1.68M - - 3.24M
Net Income After Extraordinaries (60.79M) (5.26M) (47.8M) (11.55M) (4.32M)
Preferred Dividends 2.77M 2.8M 2.33M 0 0
Net Income Available to Common (63.56M) (9.75M) (50.13M) (11.55M) (7.56M)
EPS (Basic) (1.38) (0.14) (0.86) (0.17) (0.05)
Basic Shares Outstanding 45.9M 58.03M 58.05M 68.44M 80.74M
EPS (Diluted) (1.38) (0.14) (0.86) (0.17) (0.05)
Diluted Shares Outstanding 45.9M 58.03M 58.05M 68.44M 80.74M
EBITDA (25.01M) (6.35M) (2.62M) (20.61M) (11.29M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)
